Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Table 3 Univariate analysis of PFS for second-line treatment in advanced ESCC patients \((\bar x \pm s) \)

Characteristics		n	PFS (months)	χ²/F	P
Gender	Male	54	3.43 ± 0.35	0.705	0.401
Gender	Female	6	6.33 ± 2.67	0.705	0.401
Age (years)	≤ 60	36	4.13 ± 0.62	1.533	0.216
Age (years)	>60	24	3.20 ± 0.49	1.533	0.216
Staging (2-line therapy)	IIIB	5	4.70 ± 0.62	4.704	0.095
	IVA	9	6.50 ± 4.27
	IVB	46	3.37 ± 0.41
ORR	CR + PR	14	11.57 ± 2.73	17.637	<0.001
ORR	SD + PD	46	2.93 ± 0.34	17.637	<0.001
DCR	CR + PR + SD	39	6.50 ± 1.11	64.873	<0.001
DCR	PD	21	1.57 ± 0.10	64.873	<0.001
T Stage	0	23	2.83 ± 0.64	5.453	0.141
	2	4	6.37 ± 3.75
	3	27	4.10 ± 0.66
	4	6	3.63 ± 0.96
N Stage	0	9	2.83 ± 0.80	1.549	0.671
	1	15	6.33 ± 1.07
	2	9	2.93 ± 0.15
	3	27	3.67 ± 0.43
M Stage	0	15	4.70 ± 1.80	3.187	0.074
M Stage	1	45	3.43 ± 0.38	3.187	0.074
Location	Upper	8	3.70 ± 1.89	4.172	0.124
	Middle	35	3.70 ± 1.10
	Lower	17	3.20 ± 0.55
Differentiation	Poor	7	8.07 ± 3.70	2.224	0.329
	Moderate	51	3.63 ± 0.26
	Well	2	1.90 ± 0.00
PNI Value After 2 Cycles	≥ 45	39	4.10 ± 0.70	1.332	0.248
PNI Value After 2 Cycles	<45	21	3.37 ± 0.61	1.332	0.248
PNI Value Before Enrollment	≥ 45	41	3.70 ± 0.36	0.196	0.658
PNI Value Before Enrollment	<45	19	3.37 ± 0.63	0.196	0.658
Treatment Plan	Chemotherapy	30	3.37 ± 0.48	3.897	0.048
Treatment Plan	Camrelizumab Combined Chemotherapy	30	4.70 ± 1.57	3.897	0.048
Previous Radical Surgery	Yes	27	2.83 ± 0.49	4.186	0.041
Previous Radical Surgery	No	33	4.70 ± 1.46	4.186	0.041
Previous Radical Chemoradiotherapy	Yes	16	4.70 ± 2.63	0.475	0.491
Previous Radical Chemoradiotherapy	No	44	3.57 ± 0.28	0.475	0.491

ISSN: 1477-7819